Further investigation of heterogeneity in the p53 response across chemotherapeutics used to for CRC would enhance our understanding of what the most important p53 targets are in treatment of CRC, personalize predictive/prognostic biomarkers for patients based on their p53 status, suggest potential combination therapies, and provide an explanation for drug-specific efficacy and/or toxicity across p53 status. Here, TP53 is linked to colorectal carcinoma.